XELOX (Capecitabine and Oxaliplatin)

DRUG3 trials

Sponsors

AstraZeneca, Gruppo Oncologico Italiano di Ricerca Clinica, Fudan University

Conditions

Locally Advanced Colorectal CancerLocally Advanced Rectal Cancer (LARC)Metastatic Colorectal Cancer

Phase 2

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

Not yet recruitingNCT07381777

Gruppo Oncologico Italiano di Ricerca ClinicaLocally Advanced Rectal Cancer (LARC)

Start: 2026-01-31End: 2030-12-31Target: 270Updated: 2026-02-02

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Not yet recruitingNCT07503639

Fudan UniversityLocally Advanced Colorectal Cancer

Start: 2026-04-01End: 2030-04-01Target: 134Updated: 2026-03-31

Phase 3

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

CompletedNCT00399035

AstraZenecaMetastatic Colorectal Cancer

Start: 2006-11-30End: 2016-08-31Updated: 2016-12-28

Related Papers

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

2013-03-1614 citations